Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Irvine Scientific introduces chemically-defined natural killer cell expansion medium for immunotherapy and translational research applications

Irvine Scientific logo 8.8.18Cell culture media specialist Irvine Scientific has introduced PRIME-XV® NK Cell CDM as the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex-vivo expansion of NK cells while preserving cell potency and functionality.

Current approaches to immunotherapy focus on harnessing the power of the body’s immune system to treat tumours with cell therapiesand NK cells represent one of the promising therapies as they have the potential to recognize and kill cancer cells. Studies have shown that NK cells possess the ability to identify certain tumour cells or virus-infected cells and destroy them by injecting cell-degrading proteins into the malignant cells. However, NK cells are not naturally abundant in vivo, which presents a significant obstacle to their use in NK-mediated therapies and, therefore, the challenge is to produce sufficient numbers of cells that are cytotoxic towards cancer cells ex vivo to produce effective therapies.  

A number of protocols have been developed to generate potent NK cells in sufficient numbers, but many popular methods present challenges for developing clinical applications due to their use of animal-derived components, such as serum and feeder cells. Co-culture systems with feeder cells are highly complex and variable, and there are legitimate concerns about undesirable components or genetic material transferring to the therapeutic cells as a consequence of the process. PRIME-XV® NK Cell CDM is the first commercially-available medium formulated to address this issue.

Designed for use in NK cell-based immunotherapy research and translational applications, this new medium delivers strong cell growth while also maintaining NK cell potency and functionality without the need for serum supplementation in either the presence or absence of feeder cells. The innovative formula offers researchers the option of avoiding many of the disadvantages associated with the use of feeder cells while maintaining the characteristic morphology and cytotoxicity of NK cells.

For further information about Irvine Scientific visit www.irvinesci.com

Last modified onTuesday, 07 August 2018 03:50